Topic

Articles

The collaboration, which has been in place since 1998, will focus on drug discovery, translational medicine research, and pharmaceutical development.

Sygene to Extend its Research Collaboration with Bristol Myers Squibb

Projects led by collaborating researchers from both Sanofi and Stanford Medicine will focus on autoimmune diseases and inflammatory conditions.

Sanofi Forms Three-Year Immunology Research Collaboration with Stanford Medicine

Eli Lilly and Company has partnered with leading diabetes tech firms to offer app compatibility with insulin smart pens to streamline diabetes management with automated data collection.

Lilly Forms Pact with Diabetes Tech Companies to Integrate Connected Insulin Pen Solutions

Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.

Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment

Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary, which includes a 32,400 ft2 facility in Gosselies, Belgium.

Catalent to Acquire New Facility in Belgium for Commercial-Scale Plasmid DNA Manufacturing

Moderna has entered into an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of its COVID-19 vaccine to the 92 Gavi COVAX Advance Market Commitment low- and middle-income countries. 

Moderna to Supply Up to 500 Million COVID-19 Vaccine Doses to Low- and Middle-Income Countries

This new collaboration between Vyant Bio, Ordaōs Bio, and Cellaria mitigates risk in the drug discovery process using artificial intelligence and in-vitro “avatar” clinical trials.

Vyant Bio, Ordaōs Bio, and Cellaria, Collaborate on Biomarker-Specific Small Protein Therapeutics

Through the acquisition, Pfizer will have access to Amplyx’s lead compound, Fosmanogepix (APX001), an investigational asset under development for the treatment of invasive fungal infections.

Pfizer to Acquire Amplyx Pharmaceuticals

Moderna’s investments will double the formulation fill/finish and drug substance manufacturing of its vaccine to up to three billion doses in 2022 at various manufacturing sites. 

Moderna Announces Additional Investments to Increase COVID-19 Vaccine Supply for 2022

Under the terms of the agreement, Catalent will handle the process development and CGMP manufacturing of AavantiBio’s adeno-associated viral vector-based therapeutic candidate for use in clinical trials in the US and Europe.

Deals, Development and Manufacturing